Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study reveals COVID-19's toll on cancer patients

NCT ID NCT04393974

Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 3820 adults with cancer who also had COVID-19. Researchers collected routine medical data to describe symptoms and identify factors affecting survival. The goal was to learn more about how COVID-19 affects cancer patients, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,820 people

The number who actually took part.

Started

Apr 2020

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients 18 years old or above with cancer and who have also tested positive for Sars-Cov2.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The investigators will evaluate and include consecutive patients observed in the outpatients and inpatients facility of the study centre meeting all the following CRITERIA: 1. Be ≥18 years of age. 2. Have a confirmed diagnosis of malignancy of any type. 3. Have a confirmed diagnosis of SARS-CoV-2 infection. Exclusion Criteria: Patients will not be entered in the study database when one or more of the following CRITERIA are present: 1. Unconfirmed diagnosis of SARS-CoV-2 infection 2. Insufficient clinical/follow up data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer COVID-19 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer SARS-COV2

Contacts and locations

Locations

  • ASST Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, Italy

  • Azienda Istituti Ospitalieri di Cremona

    Cremona, Italy

  • Azienda Ospedaliera Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara

    Novara, Italy

  • Azienda Ospedaliero Universitaria SS. Antonio e Biagio e Cesare Arrigo

    Alessandria, Italy

  • Chelsea & Westminster Hospital, Chelsea & Westminster Hopsital NHS Foundation Trust

    London, SW10 9NH, United Kingdom

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Fondazione Poliambulanza Istituto Ospedaliero

    Brescia, Italy

  • Guy's & St Thomas' NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • Hospital Clínic de Barcelona

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Humanitas Research Hospital

    Milan, Italy

  • Imperial College Healthcare NHS Trust

    London, W12 0HS, United Kingdom

  • Institut Català d'Oncologia Badalona

    Badalona, Spain

  • Institut Català d'Oncologia Hospital Josep Trueta

    Girona, Spain

  • Institut Gustave Roussy

    Villejuif, France

  • Institut Jules Bordet

    Brussels, Belgium

  • Ludwig-Maximilians-Universität München

    Munich, Germany

  • Northumbria Healthcare NHS Foundation Trust

    Newcastle, NE27 0QJ, United Kingdom

  • Policlinico Universitario Campus Bio-Medico

    Rome, Italy

  • St Bartholomew's Hopsital, Barts Health NHS Trust

    London, EC1A 7BE, United Kingdom

  • University College Hospital, University College London Hospitals NHS Foundation Trust

    London, NW1 2BU, United Kingdom

  • Velindre Cancer Centre, Velindre University NHS Trust

    Cardiff, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.